AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01237756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measurement of left and right lung ventilation
Description: Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
Study NCT03624881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation with EPU
Description: Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
Study NCT00388349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00388349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT00388349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Study NCT00388349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00388349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00388349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous HCT
Study NCT01365923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil effect site-TCI 2-4ng/ml
Study NCT01365923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine with remifentanil
Description: remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
Study NCT03178214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infacort
Description: Immediate-release multiparticulate formulation of hydrocortisone.
Study NCT03178214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Immediate-release multiparticulate formulation of hydrocortisone.
Study NCT03433079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL)
Description: Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.
Study NCT03433079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial lactate
Description: Arterial lactate level was assessed in all patients.
Study NCT03433079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6 (IL-6)
Description: The level of interleukin-6 was assessed in all patients.
Study NCT03433079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin (PCT)
Description: The level of procalcitonin (PCT) was assessed in all patients.
Study NCT01186263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA for diagnostic SPECT imaging
Description: Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
Study NCT01186263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic B20- SPECT imaging.
Description: Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
Study NCT01064063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard CR
Description: The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
Study NCT01064063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AGC knee
Description: The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
Study NCT01766440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 mcg/g ointment
Description: Topical ointment; twice daily application
Study NCT04750317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.
Study NCT03183453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological treatment
Description: Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
Study NCT02818309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesogaberan
Description: 120 mg bid
Study NCT02818309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05694390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of sterile transparent film dressing
Description: The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed. The infiltration scale for infants, , the criteria of extravasation (Redness accompanied by a vesicle, tissue necrosis, and ulcer), and The Phlebitis Scale were used to evaluate the catheter site.
Study NCT01082770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEGO
Description: A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
Study NCT01082770 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
Study NCT03766789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell phone application
Description: cell phone to organize medications
Study NCT04444817 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started. Furthermore, calcineurin inhibitors-based immunosuppression will be used (initial dose based on the patients' body weight) with the goal of tough levels of 3-7 ng/mL in the first seven days after liver transplantion, depending on immune status and indication for transplantation. Further tough levels will be determined based on factors such as patients' history and indication for liver transplant.
Study NCT04372017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.
Study NCT04372017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
Study NCT03433079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myoglobin
Description: The level of myoglobin was assessed in all patients.
Study NCT01737554 — intervention group
Intervention type: OTHER
Intervention: Catheter Resistance Monitoring
Description: Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
Study NCT03497936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's Stories
Description: Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
Study NCT02666781 — intervention group
Intervention type: OTHER
Intervention: ApneaLink Plus, BIA Device
Description: The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
Study NCT03224208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
Study NCT03224208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle
Study NCT00688116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA 9090 (ganetespib)
Description: This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
Study NCT00627393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antimicrobial therapy
Description: Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
Study NCT00627393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antimicrobial therapy
Description: Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
Study NCT00627393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Description: Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10\^10 per collection (or proportionately less for participants less than 30 kg in weight).
Study NCT00627393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF/dexamethasone
Description: Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
Study NCT00627393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apheresis machine
Description: Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
Study NCT03513770 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wrist-to-elbow (W-E) occlusion
Description: An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated.
Study NCT03513770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist-to-elbow (W-E) occlusion
Description: An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated.
Study NCT03513770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine
Description: In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( \~40-60 ml) will be infused into the occluded forearm at a rate of \~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
Study NCT03513770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline control
Description: In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
Study NCT03088696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stimulation
Description: activation of the acupuncture point
Study NCT03088696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no stimulation
Description: no activation of the acupuncture point
Study NCT00593346 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: brachytherapy (radioactive implants)
Study NCT02954536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT02954536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT02954536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT02954536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT02954536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
Study NCT02954536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
Study NCT01064388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: IV infusion, 15 days
Study NCT01064388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion, 15 days
Study NCT03792633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19
Description: huCART19 infusion
Study NCT02818959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JenaValve Pericardial TAVR System
Description: The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
Study NCT04428073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covax-19™
Description: Therapeutic vaccine for SARS-CoV-2 infection
Study NCT02306330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Malditof
Description: Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
Study NCT02306330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical microbiology
Description: Pathogens will be identified by the routine clinical microbiology of the hospital.
Study NCT04281290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
Description: Procedure: Electrochemotherapy Exploration, anesthesia, pancreatic cancer resection, bleomycin administration, electroporation, formation of all anastomoses.~Device: Cliniporator Vitae® Positioning of plate electrodes according to landmarks, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization, approximately 1000V/cm), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.~Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP) Intravenous bolus administration of bleomycin (15 mg/m2)
Study NCT01359488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRS-317
Description: VRS-317 Single Dose
Study NCT01359488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRS-317
Description: VRS-317 Single dose
Study NCT02803788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron, ondansetron, dexamethasone
Description: prevention of post-operative nausea vomiting
Study NCT02803788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron, ondansetron, dexamethasone
Description: prevention of post-operative nausea vomiting
Study NCT00521079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy ON
Description: Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
Study NCT00521079 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapy OFF
Description: Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
Study NCT02524327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolbox: Automated group
Description: A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
Study NCT02524327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual group
Description: The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
Study NCT00706368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care tests
Description: Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
Study NCT04552951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Single doe of 100.000 IU
Study NCT02121223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: post-dilatation with a Quantum Maverick balloon
Description: post-dilatation with a Quantum Maverick balloon at high pressure (>=16atm) for at least 15 seconds.
Study NCT02121223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manual thrombus aspiration + Promus Element stent implant
Description: manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
Study NCT02121223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual thrombus aspiration + Promus Element stent implant
Description: manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
Study NCT04426422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: treated with metformin 1500-2000mg daily
Study NCT02333435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: 3g/day of purified EPA , capsules, taken once daily, for 14 months
Study NCT02333435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months